# A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat

Source: https://onco.cc/trials/nct03075696/  
OnCo record `nct03075696` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Glofitamab, Obinutuzumab, Tocilizumab in non-hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT03075696 by Hoffmann-La Roche, with 940 participants planned, started 2017-02-21 and due to reach its primary completion in 2029-03-30. Interventions recorded: Glofitamab, Obinutuzumab, Tocilizumab. Conditions listed: Non-Hodgkin's Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03075696
- Phase: 1/2
- Setting: A Multicenter, Open-label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- Sponsor: Hoffmann-La Roche
- Enrolled: 940

## Sources

- ClinicalTrials.gov NCT03075696: https://clinicaltrials.gov/study/NCT03075696

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Glofitamab](https://onco.cc/drugs/glofitamab/), [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Tocilizumab](https://onco.cc/drugs/tocilizumab/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct03075696.json